Specialty Pharmacy

Ustekinumab is a medication used to treat and manage inflammatory conditions, including psoriasis, psoriatic arthritis, and inflammatory bowel disease.

Adalimumab-aaty (Yuflyma) prefilled syringes and autoinjectors are now fully interchangeable with the reference product adalimumab (Humira) across marketed dosage forms and strengths.

In a phase 3 study, 57% of patients treated with icotrokinra achieved an Investigator's Global Assessment score of 1 or 0 and a grade 2 or more improvement at week 16.

The investigators of a study also found that patient satisfaction with long-acting injectable antiretroviral therapy was equally as high when comparing home and clinic administration.

The role of the community pharmacist is beginning to expand into specialty pharmacy spaces to increase access and outcomes for patients.

The FDA approved adalimumab-aaty in May 2023 for 8 indications, including rheumatoid arthritis, psoriatic arthritis, Crohn disease, ulcerative colitis, and plaque psoriasis.

Data from the HERCULES phase 3 trial were presented at the 2025 Annual Meeting for the American Academy of Neurology for non-relapsing secondary progressive multiple sclerosis.

Among the drugs presented, Biktarvy and lenacapavir, teropavimab, and zinlirvimab (LTZ) demonstrate rates of suppression of HIV, and vesatolimod is well tolerated.

Additional data shows that an investigational drug, given every 4 months with Apretude, kept viral levels suppressed for patients who were already on stable treatment.

These findings are shared as late-breaking data at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) being held in San Francisco, California.

A PDUFA target action date for the PrEP therapy has been set for June 19, 2025.

Patients who achieved clinical remission at 1 year in VIVID-1 maintain clinical remission at 92.9% at 2 years with the Crohn Disease Activity Index.

Tocilizumab-anoh is the biosimilar formulation for ACTEMRA, a medication used to treat rheumatoid arthritis, COVID-19, and other diseases.

The Federal Trade Commission released its second interim staff report on industry-leading pharmacy benefit managers and their practices specifically regarding specialty drugs.

A tour of modern antiretroviral and pre-exposure prophylaxis therapies included the latest updates in HIV management and prevention.

Jay Holloway, PharmD, AAHIVP, Pharmacist with the AIDS Healthcare Foundation, joined Drug Topics to discuss the role pharmacists play in providing care for people with HIV.

Jay Holloway, PharmD, AAHIVP, Pharmacist with the AIDS Healthcare Foundation, discussed the ongoing developments impacting patients with HIV and their prescription drugs.

Cassandra Esperant, PharmD, AAHIVP, discussed the ups and downs of her career journey as a clinical HIV pharmacist.

The data from PURPOSE 2 will be published in The New England Journal of Medicine.

Cassandra Esperant, PharmD, AAHIVP, leverages her expertise as a clinical pharmacist to advocate for the well-being of individuals with HIV.

Researchers from Celltrion USA presented their post hoc analysis from the LIBERTY studies at the American College of Gastroenterology 2024 Annual Scientific Meeting.

Johnson & Johnson announced results from its phase 3 GRAVITI trial exploring guselkumab’s results in subcutaneous (SC) induction and maintenance therapy for treating Crohn’s disease.

Three posters showcased at IDWeek 2024 focused on enhancing access to HIV prevention and treatment, as well as increasing uptake of pre-exposure prophylaxis (PrEP) among women.

The first-line B/F/TAF regiment was evaluated in Hispanic/Latino patients, as well as in those with chronic kidney disease.

Individuals living in rural areas can benefit from pharmacy-based pre-exposure prophylaxis programs.

Guselkumab is currently approved by the FDA to treat adults with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, and adults with moderately to severely active ulcerative colitis.

Gilead said data from the study will support global regulatory filings that the company plans to begin by the end of the year.

Results from HERCULES will form the basis for future discussions with global regulatory authorities, according to Sanofi.

Full efficacy and safety results for the phase 3 PURPOSE 1 trial were announced by Gilead at AIDS 2024.

PASO DOBLE is the largest head-to-head, phase 4 randomized clinical trial comparing DTG/3TC and BIC/FTC/TAF in patients with HIV.